AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02455453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Study NCT02455453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Study NCT04141397 — intervention group
Intervention type: GENETIC
Intervention: Initiation of POG-related WGTA
Description: POG-related WGTA generally involves collecting biopsy samples, applying whole-genome and transcriptome sequencing, and using bioinformatics analysis to interpret sequence data and inform clinical decision-making.
Study NCT04141397 — intervention group
Intervention type: GENETIC
Intervention: Usual care
Description: Usual care, not involving the initiation of POG-related WGTA
Study NCT00368459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raloxifene
Description: Raloxifene is a selective estrogen receptor modulator
Study NCT00368459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical appearing placebo
Study NCT02794688 — intervention group
Intervention type: PROCEDURE
Intervention: Ductal lavage therapy
Description: 1. Patient lies in supine position, with routine sterilizing and draping procedure.~2. Local anesthesia with 2ml lidocaine (1%) around the nipple.~3. Identification of 4-5 openings of the lactiferous ducts from the nipple.~4. Insertion of all infusion cannula (21-23G ) into the identified openings of the lactiferous ducts.~5. Start the infusion pump with 15ml irrigation solution (2% Lidocaine 5ml, Triamcinolone acetonide 40mg，0.9% saline 10ml and ceftriaxone 1.0g). If the patients had elevated white blood cell count and fever (>38 celsius degree), oral intake or infusion of antibiotics were allowed, when necessary.~6. The patient returns to the clinic the next day, with the irrigation solution staying in the lactiferous ducts overnight, and receives breast massage.~7. Repeat step 1-6 every other day for 2 weeks.~8. Fine needle aspiration is allowed. Oral intake of corticosteroids, excisional drainage or surgery are not allowed.
Study NCT01515098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Freeze-dried blueberries
Description: Wild blueberries, freeze-dried and pulverized
Study NCT01515098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose Placebo
Description: Placebo developed to closely match blueberry powder.
Study NCT03472937 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcervical Foley catheter placement for cervical ripening
Description: Subjects will be randomized have cervical ripening with a transcervical Foley catheter in either the inpatient or outpatient setting.
Study NCT05386290 — intervention group
Intervention type: DRUG
Intervention: Infliximab
Description: A TNFα inhibitor in UC and CD treatment
Study NCT05386290 — intervention group
Intervention type: DRUG
Intervention: Vedolizumab
Description: An integrin receptor antagonist in UC and CD treatment
Study NCT05386290 — intervention group
Intervention type: DRUG
Intervention: Ustekinumab
Description: An IL-12/IL-23 inhibitor in CD treatment
Study NCT05386290 — intervention group
Intervention type: DRUG
Intervention: conventional treatment (glucocoticoid, immunosupressive drugs and/or mesalazine)
Description: Conventional treatment includes glucocoticoid, immunosupressive drugs and/or mesalazine. Immunosupressive drugs include azathioprine (AZA), methotrexate (MTX) and thalidomide (THA).
Study NCT00893074 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dronabinol 30mg/day
Description: 10mg dronabinol administered 3x/day for 5 days
Study NCT00893074 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dronabinol 60mg/day
Description: 20mg dronabinol administered 3x/day for 5 days
Study NCT00893074 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dronabinol 120mg/day
Description: 40mg dronabinol administered 3x/day for 5 days
Study NCT00893074 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: placebo dronabinol administered 3x/day for 5 days
Study NCT04957212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: An initial dose of 8 mg/kg, followed by 6 mg/kg every 3-weeks
Study NCT04957212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: An initial dose of 8 mg/kg, followed by 6 mg/kg every 3-weeks
Study NCT04957212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: An initial dose of 840 mg, followed by 420 mg every 3-weeks
Study NCT04957212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: An initial dose of 840 mg, followed by 420 mg every 3-weeks
Study NCT04957212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: A dose of AUC6 (area under the plasma concentration-time curve) every 3-weeks
Study NCT04957212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: A dose of AUC6 (area under the plasma concentration-time curve) every 3-weeks
Study NCT04957212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2 every 3-weeks
Study NCT04957212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 every 3-weeks
Study NCT04233242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical management informed by HIV-1 genotypic resistance testing
Description: The study intervention will consist of the following components:~1. Genotypic resistance testing (GRT);~2. Review of GRT results by an expert committee providing a treatment recommendation;~3. GRT-based decision on further therapy (switch or maintain current ART regimen; choice of regimen); and~4. GRT-informed adherence support.
Study NCT02859350 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
Study NCT02859350 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge (for CHMI)
Description: live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
Study NCT02859350 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PfSPZ Challenge (for CHMI)
Description: live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
Study NCT02859350 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% Sodium chloride
Study NCT02859350 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge (for PfSPZ-CVac)
Description: live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge)
Study NCT02785562 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of PDL1 expression
Description: Intervention : 2 biopsy slides will be analyzed in central laboratory.
Study NCT02963948 — intervention group
Intervention type: BEHAVIORAL
Intervention: the SAAS survey
Description: Medical staff will be surveyed using the Substance Abuse Attitude Survey (SAAS) to gather information about attitudes from medical staff who do not participate in the focus groups, or may be uncomfortable sharing negative attitudes in a group of their peers. The SAAS is a validated multidimensional instrument that evaluates physician attitudes toward substance-using patients. It includes specific measures of attitudes toward permissiveness, treatment intervention, stereotypes, treatment optimism, and moralism, and has been used in prior studies of primary care physicians. Collecting information on staff attitudes toward substance users and substance use interventions will be helpful to inform about any sources for low adoption of the tools, and any needs for additional provider education and training.
Study NCT02963948 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient surveys
Description: Patient surveys regarding attitudes toward substance use screening and interventions in the primary care clinic will be distributed to patients presenting for care, regardless of whether they completed screening, at regular time periods throughout this study phase. The survey will be conducted for 1 week at the following approximate intervals following successful implementation: 1 month, 4 months, 7 months, and 10 months
Study NCT02318615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate Axillary Plasty
Description: Immediate Axillary Plasty would be performed to reduce the formation of scar in the axilla.
Study NCT01939353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTN SR
Description: CTN SR tablets
Study NCT01939353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: CTN SR-matching placebo tablets
Study NCT02397551 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF/ICSI
Study NCT02397551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Chorionic Gonadotropin
Description: Given in different doses and timing to support the luteal phase
Study NCT00527761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 20 mg in 500 ml of normal saline by vein over 60 minutes daily for 4 days starting on day 1 of chemotherapy.
Study NCT00527761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Starting dose 20 mg by vein over 1 hour, once a week, for three weeks (on Days 1, 8, and 15).
Study NCT00527761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temodar
Description: 150 mg by mouth (PO) on Days 1 - 5.
Study NCT00387244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision for Spinal Cord Stimulation
Description: Precision System aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable back pain, and leg pain.
Study NCT01730378 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prepandrix™
Description: 2 doses administered intramuscularly in the deltoid region of arm (non-dominant arm at Day 0 and dominant arm at Day 21).
Study NCT01730378 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™
Description: 1 dose administered intramuscularly in the deltoid region of non-dominant arm.
Study NCT02983175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound assessment of gastric content
Description: Achievement of gastric ultrasound (specific procedure) :~Gastric ultrasound is performed specifically for the study by a senior anesthetist physician in a patient placed supine, semi-sitting by an angle of 45 ° relative to the horizontal.~Standardised achievement of the antral ultrasound by the following method:~* First, a qualitative assessment of antral contents in 3 grades according to the Perlas method \[24\].~* Second, performing a quantitative analysis of antral contents calculating the CSA.~* Then, volume of gastric contents calculation as from the CSA.
Study NCT03909737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin to pregnant women
Description: Azithromycin to pregnant women at antenatal care visits and during delivery
Study NCT03909737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin to infants
Description: Azithromycin to infants at 6 and 14 week EPI visits
Study NCT03909737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to pregnant women
Description: Placebo to pregnant women at antenatal care visits and during delivery
Study NCT00955708 — intervention group
Intervention type: DEVICE
Intervention: ACUITY Spiral Left Ventricular Lead
Description: The implant of the ACUITY Spiral Lead
Study NCT00514579 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cord blood transplantation
Description: Myeloablative preparative regimen of chemotherapy and radiation followed by double unit umbilical cord blood transplantation
Study NCT01405651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-6950
Description: 30 mg, 100 mg, 300 mg at multiple doses
Study NCT01405651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-6950
Description: Placebo to match ONO-6950 tablets dosed in a similar manner to ONO-6950
Study NCT02002962 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation
Study NCT02002962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A injection
Study NCT04723290 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serological tests for SARS Cov-2
Description: Each participant will have a blood test on a dry tube of maximum 8 ml of whole blood
Study NCT01991327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal
Study NCT01991327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT03296800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexagliflozin
Description: Bexagliflozin 20 mg, tablet; qd
Study NCT03296800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: Probenecid tablets, 500 mg; bid
Study NCT03296800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin, 600 mg (2 x 300 mg capsules); qd
Study NCT03296800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Verapamil hydrochloride tablet, 120 mg; qd
Study NCT05977205 — intervention group
Intervention type: OTHER
Intervention: No interventions, observational study
Description: Not applicable, no interventions, observational study
Study NCT00737477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta
Description: Mircera will be administered SC every 4 weeks for a total of 48 weeks. The first dose of 120 or 200 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
Study NCT04139382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Consultation
Description: A telephone consultation comprising clinical history, contraception planning, explanation of medical method of abortion
Study NCT04139382 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-Face Consultation
Description: A face-to-face consultation comprising clinical history, contraception planning, explanation of medical method of abortion
Study NCT01024153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active video game play
Description: Children will get a Wii video game console and one game at week one and another at week 7. We will monitor their video game play and physical activity during this time.
Study NCT00581477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa Oral Product
Description: Droxidopa administered in increasing dosages up to 300 mg
Study NCT01968889 — intervention group
Intervention type: OTHER
Intervention: Non invasive phrenic nerve stimulation
Description: Non invasive phrenic nerve stimulation allowing to measure the twitch airway pressure during airway occlusion
Study NCT00667394 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.
Study NCT03909737 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to pregnant women
Description: Placebo to pregnant women at antenatal care visits and during delivery
Study NCT00667394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN-518 (Tandutinib)
Description: Tandutinib 500 mg by mouth daily dose twice a day.
Study NCT00667394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Forty-five one-sentence questionnaire to assess health related quality of life in patients with brain cancer.
Study NCT02838992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabbit ATG, (Genzyme)
Description: ATG is an infusion of rabbit-derived antibodies against human T cells, which is used in the prevention and treatment of acute rejection in organ transplantation and therapy of aplastic anemia
Study NCT02838992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit ATG, (Genzyme)
Description: ATG is an infusion of rabbit-derived antibodies against human T cells, which is used in the prevention and treatment of acute rejection in organ transplantation and therapy of aplastic anemia
Study NCT02838992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cy
Description: Cyclophosphamide is a medication mainly used in chemotherapy. It is an alkylating agent of the nitrogen mustard type
Study NCT02838992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CsA
Description: CsA is an immunosuppressant drug widely used in organ transplantation to prevent rejection. It reduces the activity of the immune system by interfering with the activity and growth of T cells
Study NCT02838992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA
Description: CsA is an immunosuppressant drug widely used in organ transplantation to prevent rejection. It reduces the activity of the immune system by interfering with the activity and growth of T cells
Study NCT02838992 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord blood
Description: Cord blood is blood that remains in the placenta and in the attached umbilical cord after childbirth. Cord blood is collected because it contains stem cells, which can be used to treat hematopoietic and genetic disorders
Study NCT00332462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine (Sandimmun® i.v.)
Description: Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
Study NCT00332462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine (Sandimmun® Optoral)
Description: Sandimmun® Optoral microemulsion oral capsule twice daily starting at an initial daily dose of 8-12 mg/kg/day. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
Study NCT02377167 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tracheostomy
Description: Tracheostomy is performed as percutaneous dilatative tracheostomy with tracheostomy kit by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
Study NCT02377167 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheostomy
Description: Tracheostomy is performed as percutaneous dilatative tracheostomy with tracheostomy kit by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
Study NCT01735175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LA-EP2006
Description: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
Study NCT01735175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neulasta®
Description: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
Study NCT04974762 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration
Description: Surgical wound infiltration by proceduralist
Study NCT04974762 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Truncal blocks
Description: Truncal blocks provided by anesthesiology team for device placement
Study NCT03689777 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sleeve gastrectomy
Description: sleeve gastrectomy
Study NCT03689777 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastric bypass
Description: gastric bypass
Study NCT03867539 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Differing pain management strategy
Description: The investigators aim to investigate an alternative (vs standard) pain management strategy for post operative carpal tunnel release. All drugs used are FDA approved for these indications, and no drug itself is being investigated.
Study NCT03867539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Differing pain management strategy
Description: The investigators aim to investigate an alternative (vs standard) pain management strategy for post operative carpal tunnel release. All drugs used are FDA approved for these indications, and no drug itself is being investigated.
Study NCT01931098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: Taken .25 mg orally, daily continuous until progression up to one year.
Study NCT01931098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: 600 mg orally, daily until progression, up to one year.
Study NCT01712061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04634817
Description: Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function
Study NCT01712061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function